Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...
1d
The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...
Piper Sandler thinks Myriad Genetics (MYGN), which has seen its shares fall nearly 22% on Friday morning, is trading down on a coverage decision on GeneSight by UnitedHealth (UNH), which will take ...
UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) GeneSight, effective January 1, 2025, in a number of plans ...
Election season is in full swing, but as anyone can tell you, campaigns begin to enter their full speed much earlier in the ...
Stephens analyst Mason Carrico notes that Myriad Genetics (MYGN) shares are down about 20% this morning, which the firm ...
With a simple cheek swab, the GeneSight test generates a report that gives healthcare providers insight into how a patient may metabolize or respond to certain psychiatric medications.
BRANDON, FL, UNITED STATES, November 3, 2024 /EINPresswire / -- Learning to Achieve Wellness has carved out a unique space in the world of mental < ...
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.
Wells Fargo analyst Steve Baxter maintained a Buy rating on UnitedHealth (UNH – Research Report) yesterday and set a price target of ...
Notes from several investment houses indicate that the insurance giant will no longer cover genetic tests for behavioral health, which includes Myriad's GeneSight, beginning Jan. 1, 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback